Asset profile
KM-819
Small molecule
Evidence outlook · lead readout
NCT03022799 · Parkinson's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03022799: Participants were randomly assigned to KM-819 or placebo, with both participants and staff kept blinded to treatment, which is a well-controlled design. However, the study was conducted in healthy volunteers and tracked safety findings and drug levels across multiple dose cohorts rather than testing whether KM-819 helps Parkinson's disease itself, so it cannot speak to clinical benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.